comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Onclive institutional perspectives - Page 1 : comparemela.com
Dr Cobain on Future Considerations For the Treatment of HR+/HER2– Breast Cancer
Erin Frances Cobain, MD, discusses key takeaways from an OncLive Institutional Perspectives in Cancer webinar on breast cancer.
Michigan
United-states
Erin-frances-cobain
University-of-michigan
Rogel-cancer-center
Breast-cancer-clinical-research-team
Onclive-institutional-perspectives
Ongoing Research Drives Further Questions in Early-Stage Breast Cancer Management
Erin Frances Cobain, MD, discusses unanswered questions regarding the use of ribociclib and immunotherapy in early-stage breast cancer.
Margaret-gatti-mays
Erin-frances-cobain
Monika-burness
Breast-cancer-clinical-research-team
Alliance-for-clinical-trials-in-oncology
University-of-michigan-rogel-cancer-center
Onclive-institutional-perspectives
Michigan-rogel-cancer-center
Ann-arbor
Clinical-trials
D
Early-stage-breast-cancer
The Road Beyond Frontline CDK4/6 Inhibitors in HR+/HER2– Metastatic Breast Cancer Examines Combinations
Erin Frances Cobain, MD, highlights the current role of endocrine therapy and CDK4/6 inhibitors in HR-positive, HER2-negative metastatic breast cancer.
United-states
San-antonio
Texas
Michigan
Ann-arbor
American
Erin-frances-cobain
American-society-of-clinical-oncology-annual-meeting
University-of-michigan-rogel-cancer-center
University-of-michigan
Breast-cancer-clinical-research-team
Onclive-institutional-perspectives
Bispecific Antibodies and Noncovalent BTK Inhibitors Expand Horizons in DLBCL and MCL
Catherine C. Coombs, MD, spotlights the use of bispecific antibodies in diffuse large B-cell lymphoma and pirtobrutinib in mantle cell lymphoma.
California
United-states
University-of-california-irvine
Catherinec-coombs
Niravn-shah
Swetha-kambhampati
Department-of-medicine
College-of-wisconsin
Division-of-hematology
School-of-medicine
California-irvine
Onclive-institutional-perspectives
SOC Drugs Provide Strong Foundation For Effective Combinations in Hematologic Malignancies
Catherine C. Coombs, MD, discusses future directions for BTK inhibitors in chronic lymphocytic leukemia and combination therapies in myelofibrosis.
United-states
Catherinec-coombs
Angelag-fleischmann
Naveen-pemmaraju
Joshuaf-zeidner
International-consensus-classification
School-of-medicine
Division-of-hematology
Department-of-medicine
World-health-organization
University-of-california-irvine
Onclive-institutional-perspectives
vimarsana © 2020. All Rights Reserved.